Skip to main content
Caplight Logo









Biorelate

Biorelate

Private
ManchesterAI, Data & Cloud Infrastructurehttps://biorelate.com/

Last Round

Series A

Nov 29, 2022

Total Funding Raised

$8.98M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Biorelate is a biotechnology company that provides an AI-driven platform called Galactic AI™ for biomedical data curation to accelerate drug discovery and research.

Sector

AI, Data & Cloud Infrastructure

Verticals

Drug Discovery, Medical AI, Biotechnology, NLP & Conversational AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Subscription SaaS, Data as a Service, Services & Consulting, Usage-Based SaaS, Government Contracts

AI Layer

Application

Keywords

causal AIdrug discovery AIbiomedical knowledge graphtarget identificationnatural language processingNLPBioNLPbiomedical data curationbiomarker discoverypharma techknowledge graphlife sciences techtext miningunstructured data analysisdrug discovery APIdata as a serviceSaaS platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Biorelate Comparables

Compare Biorelate with similar companies based on industry and business-model similarity.

Biorelate comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Causaly
88%
ONTOFORCE
83%
Data4Cure, Inc.
81%

Biorelate Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 29, 2022
GrantFeb 4, 2019
SeedSep 18, 2018

Key People

Founding team and executive leadership

Daniel Jamieson

CEO and Founder

Founding Team

Biorelate Investors

Notable investors and investment history

Biorelate investors
InvestorRounds
Innovate UKGrant
Triple Point VenturesSeries A
Innovate UKGrant
YFM Equity PartnersSeries A
Catapult VenturesSeed
Maven Capital PartnersSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 264% MoM, reaching 4.6K.

  • Nov 29, 2022

    $8M round led by Maven Capital Partners and YFM Equity Partners.

Biorelate Filings

Explore SEC and related filing metadata, where available.

Biorelate filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Biorelate's valuation, stock price, and market status.

Is Biorelate a public or private company?

Biorelate is a private company.

What is the current stock price of Biorelate?

Biorelate is a private company with no public stock price. No recent secondary market data is available.

How much is Biorelate worth (valuation)?

Valuation information for Biorelate is not publicly available.

Can I buy Biorelate stock?

Biorelate shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Biorelate's last funding round?

Biorelate's most recent funding round was Series A on November 29, 2022.

Who are the main investors in Biorelate?

Key investors in Biorelate include YFM Equity Partners.

Will Biorelate IPO soon?

No public IPO plans have been announced for Biorelate.

How can I track Biorelate secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Biorelate's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersManchester
Employee Range28
Year Founded2014
Last FundingNov 29, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?